Your product is now available from Integrated DNA Technologies.
Many of the Swift products you have grown to love are now part of our new complete portfolio, xGen™ NGS. Through this new partnership we are pleased to offer you comprehensive next generation sequencing solutions.
xGen NGS—made for you.
Unsure of what products are available? Or, perhaps you’d like guidance on which products are compatible? If so, try our xGen NGS Solutions Builder Tool today.
Welcome to the IDT family!
Find Archer now at IDT!
All Archer information is now available on IDT’s website. You can view Archer assays alongside IDT’s xGen™ NGS portfolio to find the best next generation sequencing solution for your lab.
Confidently detect more with Archer NGS assay solutions for your solid tumor, blood cancer, immune profiling, and genetic disease research.
Choose your region, country/territory, and preferred language
Frequently asked questions
Our Scientific Applications Support team has assembled a list of frequently asked questions to help you find answers quickly. Filter using one or more categories to focus on specific topics, or use the search bar to perform a text search.
Search all FAQs:
How can I estimate the amount of editing obtained using the Alt-R™ CRISPR-Cas9 or -Cpf1 Systems?
We recommend using the Alt-R Genome Editing Detection Kit to determine the relative amount of editing obtained. This method uses T7 endonuclease I (T7EI) to cleave heterodimers formed in PCR amplicons following CRISPR editing.
It is important to consider that the T7EI-based assay underestimates the amount of total editing, as it does not accurately account for single-base insertions or deletions, but rather detects indels of multiple bases. Nonetheless, the Alt-R Genome Editing Detection Kit is the recommended approach for estimating editing efficiency, because of its ease of use compared to Sanger sequencing.